Clinical Trial Update: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results for GLIMMER-01, a bi-sialidase fusion protein from Palleon, tested across multiple solid tumors with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Gastric Cancer
• Head and Neck Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• GLIMMER-01 (bisialidase fusion protein)

Snippet

Sponsor: Palleon Pharmaceuticals, Inc. | Conditions: Oncology, Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-08-20